AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
ALUVI.PA

UV Germi SA (ALUVI.PA) fair value

Industrials · Pollution & Treatment Controls · Euronext Paris · France
€2.34+0.00%
Market cap €6MNext earnings 2025-04-24Updated Oct 22, 2026
Our verdict
Trades 49% below our fair value
Price
€2.34
Model fair valueConfidence: low
about €4.57
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Treated as a cyclical company. None of the usual models had enough data, so this uses Analyst consensus and Dividend discount instead.
ACCE opinionUV Germi SA (ALUVI.PA)
Fair value
Not available
ACCE price target
€3.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 23 Oct 2026, 01:53 CEST.
Price used: €2.34 at the close on 23 Oct 2026, 17:30 CEST.
Models: Analyst consensus and Dividend discount.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
44
out of 100
P/E
78.0x
forward 7.1x
1-year return
+3.1%
Dividend yield
0.00%

UV Germi SA in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

UV Germi SA is a small French maker of ultraviolet disinfection equipment, including UV water treatment and air-purification systems used in hospitals, food and pharmaceutical plants, and municipal water works. The case rests on its 42.1% gross margin, which is high for a hardware maker and suggests the installed base and consumables carry more pricing power than the thin 2.3% operating margin implies. Revenue is growing 6.4%, and with a forward P/E of 7.1 against a trailing 78.0, the market is pricing a sharp earnings recovery from a currently depressed base. The valuation gap is the main reason it merits a look, but the 1.0% ROE and a market cap of about 6M EUR mean liquidity and governance questions need answering before any position could be sized.

AI-assisted·How I use AIWritten Oct 23, 2026

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where ALUVI.PA's valuation models land
Price
€2.34
Model fair valueConfidence: low
about €4.57
Model
Fair value
Upside
Analyst consensus
Dividend discount
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
-4.5%
1 month
-7.1%
3 months
-7.5%
6 months
+1.3%
YTD
-20.1%
1 year
+3.1%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
23 Oct 2026, 01:53 CESTACCE price target€3.00first publication€2.34

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in EUR. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full ALUVI.PA page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth28Value47Quality46Momentum54Total44
Valuation
Trailing P/E
78.0x
Forward P/E
7.1x
PEG
no data
P/B
0.61x
EV / Revenue
0.2x
Book value/sh
€3.10
Enterprise value
€1M
Profitability
ROE
1.0%
FCF yield
no data
ROIC
0.8%
Health and risk
Debt / equity
0.02
Dividend yield
0.00%
Beta
0.31

Price

+4.0% · 1Y

Ask anything about ALUVI.PA

Answered from UV Germi SA fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 50% of peers
low 0.0x78.0xhigh 88.0x
ROEbetter than 83% of peers
low -5812%1%high 1%
Div yieldbetter than 100% of peers
low 0.0%0.0%high 0.0%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
ALUVI.PA UV Germi SA€2.34--78.0x1.0%4644
RAIN Rain Enhancement Technologies Holdco Inc. Class A Common Stock$0.62---0.0%1614
SAXG.ST Saxlund Group AB (publ)kr 8.40kr 1017% below84.0x1.3%4628
BAWAT.ST Bawat Water Technologies ABkr 1.07----5811.5%2542
CLWT Euro Tech Holdings Company Limited Common Stock$1.32--67.5x1.0%4242
LIQT LiqTech International Inc. Common Stock$0.35----49.6%1722
ALTUV.PA BIO-UV Group S.A.€0.89--88.0x0.5%5136

Sector report card

Where ALUVI.PA ranks against its sector peers on each metric.

Computing percentiles…